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Objectives: To study possible associations and assess the impact of socio-demo-
graphic, quality-of-life and coping factors on the severity of Crohn’s disease patients 
in Israel. MethOds: Consecutive Crohn’s disease patients undergoing clinical follow-
up at the Inflammatory Bowel Diseases Clinic completed the following question-
naires: SF-36 quality-of-life, Ways of Coping, and socio-demographic details. Crohn’s 
disease severity was measured by Harvey-Bradshaw Index (HBI) expanded to include 
pharmaceutical and surgical therapies as well as medical and surgical hospitalization 
information. Based on these data, a multifactorial model was built using multivariate 
linear regression. Results: There were altogether 192 patients: 81 (42.2%) men (age 
36.8 ± 14.5 years, disease duration 11.4 ± 8.6 years, education 13.7 ± 2.7 years, HBI 7.6 
± 4.9) and 111 (57.8%) women (age 41.4 ± 15.6*, duration 14.0 ± 9.3*, education 14.2 ± 
2.8, HBI 8.4 ± 4.8; *p < 0.05 vs. men). The multifactorial model showed the following 
significant predictors of disease severity: age (beta = −0.250, p = 0.006), number of 
children (beta = 0.245, p = 0.008), SF-36 General Health score (beta = −0.378, p < 0.01), 
coping/sense of humor (beta = 0.209, p = 0.011), and coping/acceptance (beta = −0.183, 
p = 0.024). The model accounted for 29% of explained variance, with Adjusted R2 = 
0.26. Gender, education and socio-economic status were not predictors of disease 
severity. cOnclusiOns: All of the indicated factors (age, family size, coping skills) 
had a significant effect on the severity of Crohn’s disease. In addition to prescribing 
medications, physicians should pay special attention to these factors as part of an 
overall management plan for their Crohn’s disease patients.
PGI6
DeveloPment AnD externAl vAlIDAtIon of A rIsk CAlCulAtor for 
PreDICtInG AnemIA In PAtIents treAteD WIth trIPle therAPy (tt) 
ContAInInG BoCePrevIr (BoC), PeGylAteD Interferon AnD rIBAvIrIn (Pr)
Nwankwo C.1, Kattan M.2, Luan A.3, Wahl J.1
1Merck, Whitehouse Station, NJ, USA, 2Cleveland Clinic, Columbia, SC, USA, 3Agile 1, Torrance, 
CA, USA
Objectives: To develop and validate a risk calculator for the prediction of anemia 
occurring after 8 weeks of TT using BOC+PR among Hepatitis C Virus (HCV) genotype 
1 patients based on risk factors. MethOds: Data for all randomized HCV genotype 
1 patients starting therapy with BOC+PR and who received at least one dose of BOC 
in three phase 3 clinical trials (PN05101, PN5216 and PN5514) were included. The 
outcome of interest was the prediction of anemia, defined as hemoglobin < 10 g/L 
after 12 weeks of TT with BOC+PR (this included 4 weeks of lead-in treatment using 
PR). Logistic regression was used to develop the risk calculator model by analyzing 
the association of each variable with the likelihood of developing anemia while on 
treatment. Baseline variables were included as covariates in the model. Linearity 
assumptions were relaxed with the use of restricted cubic splines. Bootstrapping, 
with 1000 resamples, were used in conjunction with estimation of discrimination 
and calibration. Results: Following a stepdown procedure that eliminated predic-
tors that did not contribute to the overall model concordance index, nine variables 
remained in the final model: age, hemoglobin, gender, cirrhosis, hematologic counts, 
Alkaline phosphatases levels, and creatinine. This model had a boostrap corrected 
concordance index of 0.775. The model was cross-validated by sequentially omit-
ting each of the three randomized trials from the model development and using the 
omitted trial as a test set; the concordance indices following this procedure ranged 
from 0.75 to 0.85. Calibration of the model, assessed graphically, indicated reason-
ably close agreement between predicted and observed proportions. Calibration held 
following trial cross validation as well. cOnclusiOns: The model calibrated well 
and demonstrated good predictive ability. This tool may be useful for identifying 
and subsequently managing HCV patients at relatively high risk for developing 
anemia if treated with BOC+PR.
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Objectives: Hepatitis C virus (HCV) infection is one of the main causes of chronic 
liver disease worldwide. Sofosbuvir, a nucleotide analogue inhibitor of HCV RNA-
dependent RNA polymerase, has been approved in Europe for the treatment of 
chronic hepatitis C genotypes 1-6. This study aims to estimate the budget impact 
of sofosbuvir in patients who live in the Veneto Region. MethOds: Population data 
were obtained from a regional survey. The survey was conducted by the Department 
of Molecular Medicine of Padua University in order to identify the number of 
patients with advanced stage disease or more rapid disease progression. At the 
time of this study, the Italian price of sofosbuvir has not been defined so it was esti-
mated that a full 12 week course of sofosbuvir would cost as Swedish price: 42.653 
€ (85.306€ for a 24 week treatment). Total costs include costs for other drugs which 
might be used in combination. Results: In Veneto Region, there are 835 patients 
with severe Hepatitis C genotype 1 (n= 493); genotype 2 (n= 94), genotype 3 (n= 178), 
genotype 4 (n= 70) and about 40% of them need a 24 week treatment. Moreover, 
there are 100 patients awaiting liver transplantation and 70 patients with post-
transplant recurrence of HCV infection. Therefore, the total estimated expenditure 
would be about € 66.000.000 for all the 1005 patients and about € 34.000.000 for the 
455 patients (45%) with very high priority to treatment. cOnclusiOns: High prices 
for new drugs are a growing concern to payers, given the large number of innova-
tive drugs in development and the limited health care resources. Due to high costs, 
economic analyses are needed to estimate the budgetary impact for the Regional 
Health System (RHS) with sofosbuvir.
significance difference in the efficacy and safety in nucleos(t) ide-naïve CHB patients 
with HBV DNA greater than 6 log10 in the medical center.
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Objectives: To investigate the efficacy of probiotics in irritable bowel syndrome 
(IBS) patients, this meta-analysis was performed. MethOds: The collected data 
contained twenty-four clinical trials which fifteen were eligible for meta-analysis 
and nine were reviewed systematically. All studies were randomized placebo-con-
trolled trials in patients with IBS that investigated the efficacy of probiotics in IBS 
improvement. Trials were evaluated with Relative Risk (RR) with 95% confidence 
interval (95% CI). Cochran Q test was used to test heterogeneity with P value 0.05 
(P< 0.05). Egger and Begg-Mazumdar tests in funnel plot were calculated as publica-
tion bias indicators. Results: Probiotics reduced pain severity, symptom severity 
score and induced adequate general symptom improvement. Distension, bloating, 
and flatulence were not improved after probiotics treatment when compared to 
placebo. cOnclusiOns: Collectively, the results demonstrated the beneficial effi-
cacy of probiotics compared with placebo in IBS patients.
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Objectives: Hepatitis C virus (HCV) affects an estimated 130 million people world-
wide and is a major cause of chronic liver disease. Real-world data is needed to bet-
ter understand the epidemiology of HCV and its complications, as well as treatment 
patterns and outcomes. The objectve of this study is to establish a cohort of HCV 
carriers in a large health maintenance organization, with comprehensive data on 
treatment and disease outcomes. MethOds: The HCV cohort will use data available 
since 1998 from the computerized databases of Maccabi Healthcare Services, the 
second largest HMO in Israel, with approximately 2 million members. HCV cases are 
included based on diagnostic codes (ICD9-CM), laboratory data (e. g. detection of HCV 
antibodies and RNA) and dispensed prescriptions for HCV treatment. The cohort 
includes demographic data (age, sex, immigration and socioeconomic status), clini-
cal data (e. g. BMI; comorbidities), treatment patterns, virological outcomes, and HCV 
complications – including cirrhosis, hepatocellular carcinoma, liver transplants, and 
mortality. Results: At the end of 2012, HCV infection was identified among 10,648 
patients, corresponding to an age-adjusted prevalence rate of 5 per thousand. The 
highest prevalence was found among males and in the age group 35-55 yrs. Two 
thirds of HCV patients were immigrants from Eastern Europe. HCV genotype 1 was 
predominant (67%). Over a third of patients had at least one recorded purchase of 
interferon, and treated patients were less likely to have chronic diseases such as 
diabetes or cardiovascular disease, compared to untreated patients. cOnclusiOns: 
The establishment of a HCV cohort in MHS can serve as a basis for retrospective 
database studies and can be periodically updated to follow up existing patients and 
identify incident HCV cases. For example, future studies can examine the adherence 
and efficacy of treatments, and associations between HCV and chronic diseases 
such as chronic kidney disease.
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Objectives: The objective of this study was to investigate the incidence of complica-
tions (bleeding and perforation) with hospitalization from both upper and lower GI 
tract in Japanese population using a health care claims database (HDB). MethOds: 
All of the claims data of the patients who have a history of hospitalization due to 
complications from GI tracts between January 2011 and December 2012 were extracted 
from the HDB which holds about 1.8 million peoples’ claims data under employment-
based health insurance. In order to identify upper and lower GI events precisely, we 
confirmed them when a diagnosis of a GI event in the claims (ICD-10 code) was accom-
panied by a record of examination and/or endoscopic or surgical treatment relevant 
to upper and lower GI complications. Results: The total number of person-years at 
risk was 1.2 million person-years in 2012. The incidence rates in upper and lower GI 
events were 48 and 41 per 100,000 person-years, respectively. Twenty-one percent of 
the lower events originated in bleeding from hemorrhoid or related treatments (eg. 
hemorrhoidectomy). Age-group analyses in the upper vs. lower events, except those 
from hemorrhoid, were 27 vs. 17, 57 vs. 46 and 184 vs. 104 per 100,000 person-years 
in 20-39, 40-59, and 60+ years groups, respectively. Data from 2011 were consistent 
with these observations on the ratio of upper to lower GI events and the age-based 
incidence, indicating the robustness of the results. cOnclusiOns: This was the first 
study to investigate the incidence from both upper and lower GI complications with 
hospitalization in a real clinical setting in Japan using a single large data source. We 
confirmed that a number of GI events occurred in both upper and lower GI tract and 
the incidence rates of both events were increased with age in a real world setting.
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